WISDOM-II: Screening against multiple targets implicated in malaria using computational grid infrastructures
© Kasam et al; licensee BioMed Central Ltd. 2009
Received: 03 November 2008
Accepted: 01 May 2009
Published: 01 May 2009
Despite continuous efforts of the international community to reduce the impact of malaria on developing countries, no significant progress has been made in the recent years and the discovery of new drugs is more than ever needed. Out of the many proteins involved in the metabolic activities of the Plasmodium parasite, some are promising targets to carry out rational drug discovery.
Recent years have witnessed the emergence of grids, which are highly distributed computing infrastructures particularly well fitted for embarrassingly parallel computations like docking. In 2005, a first attempt at using grids for large-scale virtual screening focused on plasmepsins and ended up in the identification of previously unknown scaffolds, which were confirmed in vitro to be active plasmepsin inhibitors. Following this success, a second deployment took place in the fall of 2006 focussing on one well known target, dihydrofolate reductase (DHFR), and on a new promising one, glutathione-S-transferase.
In silico drug design, especially vHTS is a widely and well-accepted technology in lead identification and lead optimization. This approach, therefore builds, upon the progress made in computational chemistry to achieve more accurate in silico docking and in information technology to design and operate large scale grid infrastructures.
On the computational side, a sustained infrastructure has been developed: docking at large scale, using different strategies in result analysis, storing of the results on the fly into MySQL databases and application of molecular dynamics refinement are MM-PBSA and MM-GBSA rescoring. The modeling results obtained are very promising. Based on the modeling results, In vitro results are underway for all the targets against which screening is performed.
The current paper describes the rational drug discovery activity at large scale, especially molecular docking using FlexX software on computational grids in finding hits against three different targets (PfGST, PfDHFR, PvDHFR (wild type and mutant forms) implicated in malaria. Grid-enabled virtual screening approach is proposed to produce focus compound libraries for other biological targets relevant to fight the infectious diseases of the developing world.
Discovering hits with the potential to become usable drugs is a critical first step to ensure a sustainable global pipeline for innovative anti-malarial products. While the establishment of public-private partnerships has helped to stimulate product R&D for some neglected diseases, increased emphasis needs to be placed on the high-risk early discovery phase.
This paper describes an established hit discovery strategy for neglected diseases through in silico screening using computing grid infrastructures, as a very cost effective way to select the most promising drug-like molecules to address Plasmodium multi-drug resistance. Here the aim is to counter-act malaria by finding hits to multiple targets. This is so far the first large scale in silico drug finding initiative against malaria and neglected diseases.
The project fits in the drug discovery pipeline between initiatives like the TDR drug target portfolio programme , which aims at developing a prioritized drug target portfolio, and initiatives like DNDi , which address pre-clinical research on new lead compounds. WISDOM project enables the cost effective selection of focused compound libraries for drug targets to allow cheap and small scale in vitro and in vivo tests affordable by all research laboratories, even in less developed countries.
This approach builds upon the progress made in computational chemistry to achieve more accurate in silico docking and in information technology to design and operate large-scale grid infrastructures.
This paper describes the collaborative framework, which has been established between bio-informaticians, biochemists, pharmaceutical chemists, biologists and grid experts, in order to produce and make selected lists of potential inhibitors available. It also aims at publicizing the service for research laboratories interested to use it for their own preferred target.
WISDOM, a virtual docking service on grids
Due to very high costs associated to the drug discovery process as well as due to late stage attrition rates, novel and cost effective strategies are absolutely needed for combating the neglected diseases, like malaria. Virtual high throughput screening is a technique, which can screen millions of compounds rapidly, reliably and cost effectively on a computer [3, 4].
There are millions of chemical compounds available in the labs and also in 2D, 3D electronic databases due to advances in the combinatorial chemistry, but it is nearly impracticable to synthesize them . Moreover it is labour-intensive and very expensive to screen such a high number of compounds in experimental labs by high throughput screening (HTS). Besides the heavy costs (required for developing efficient and reliable assays) the hit rate in HTS is quite low .
In addition to the availability of a huge number of chemical compounds, there is also a significant increase in the number of resolved X-ray crystal structures, most of which are freely available from the Brookhaven protein database .
The presence of sound open source electronic data of chemical compounds as well as the data for macromolecules like proteins, enzymes facilitated virtual high throughput screening (vHTS). Virtual high throughput screening (vHTS) by molecular docking serves as a complementary or alternative technique to experimental high throughput screening (HTS). In silico drug design, especially high throughput virtual screening is a widely-used and well-accepted technology in new lead identification and optimization [7, 8].
The downside to vHTS is that screening millions of chemical compounds is computationally intensive: it has a high storage demand and is, therefore, termed as computational data challenge. Screening each compound, depending on structural complexity, can take from one to few minutes on a standard PC, which means screening a database with millions of chemical compounds can take years of computation time. Computational grid infrastructures are the best attempt to solving this problem thus far. The computing resources from EGEE grid infrastructure were utilized extensively [9–11], besides EGEE  several other grid infrastructures such as: AuverGrid , EELA , EUChinaGrid  and EUMedGrid  contributed significantly to the current project.
The combination of these two techniques (vHTS and Grid computing) will definitely decrease the financial and cost implications of rational drug design strategies. Several docking applications have already been run on grids and proved to be successful. Some of the success stories in in silico drug design on grid are the smallpox research grid , Anthrax research project and Cancer project [18–20].
WISDOM-I , the first large scale deployment of molecular docking application on EGEE, which took place from August 2005 to September 2005 has seen 42 million dockings, which is equivalent to 80 years of CPU. Virtual screening of 500,000 chemical compounds was performed by using FlexX against different plasmepsins (aspartic protease implicated in haemoglobin degradation). On the biological front three scaffolds were identified, one of them is guanidino scaffold, which is likely to be novel as they have not been reported as plasmepsin inhibitors before . Experimental results have proved that the some of the compounds selected from WISDOM-I function as sub-micromolar inhibitors against plasmepsin .
The main goals of WISDOM project were to identify inhibitors to be tested in the experimental laboratories and to develop fault tolerant WISDOM production environment , which is capable of deploying molecular docking application efficiently on grid infrastructure. Drug targets from malaria are chosen initially, but this could be expanded to determine ligand binding to any target protein.
The grid enabled virtual screening process
WISDOM-II, second large scale virtual screening on malaria
Structural features of the targets used in WISDOM II
Pf DHFR (wild type)
Pf DHFR (Quadruple mutant)
P vDHFR (Double mutant)
The P. falciparum glutathione S-transferase enzyme belongs to a super family of multifunctional, dimeric, phase II detoxification enzymes that can bind various xenobiotic, electrophilic substrates. Parasites as well as other rapidly dividing cells are highly dependent on a functional antioxidant defense system. For most parasites the sources of reactive oxygen species is mainly their high metabolic rate as well as oxidative stress imposed by the host's immune system. Additionally, the P. falciparum parasite performs haemoglobin degradation – a source of oxidative stress and free radicals . The antioxidant defense system of P. falciparum is mediated by an ensemble of antioxidants like glutathione as well as antioxidant enzymes .
The primary function of GST lies in the protection of cellular macromolecules. GST deactivates harmful chemicals via the nucleophilic addition of the thiol (SH) group from glutathione (GSH), to the hydrophilic moiety of the toxic agent, thus rendering the electrophilic compounds harmless and enabling the removal of the substance. Because of the inactivation of potentially hazardous substances, GST activity is beneficial to an organism's health and survival [28, 29]. In chloroquine-resistant parasites GST activity is directly and positively related to drug pressure [30, 31].
Inhibition of GST will impair the general detoxification processes and, because the enzyme has peroxidase activity, reduce the antioxidant capacity of the parasite . PfGST (EC 126.96.36.199) is a multi-functional protein consisting of two monomers. In accordance with other GST enzymes each monomer of PfGST contains an N-terminal α/β domain and C-terminal α-helical domain. The active site is defined by two binding sites: the G site, which binds GSH, and the more flexible H site, which can bind various other substrates. The monomers are predominantly held together by hydrophobic effects, but four salt bridges and four hydrogen-bonded pairs of residues also contribute to the dimerization [33, 34]. The G site is relatively rigid and not greatly affected by inhibitor binding, with the exception of the C-terminal tail and the loop connecting the α-4 and α-5 helices. This region is very specific for its natural substrate (GSH). The recognition and binding occur via a network of polar interactions between PfGST and GSH.
The hydrophobic binding pocket (H site) is considerably more variable than the G site, due to the nature of second substrates. The substrate specificity of different isozymes in the GST super family can be attributed to the variation of amino acids present in the H site consequently leading to different interactions a ligand can form with amino acids in the H site of the enzymes .
PfGST also possesses a short μ-loop. In contrast to other μ-class GST enzymes, PfGST has only five residues after α-8, which is too short to form a wall or α-helix. This feature is lacking in PfGST, resulting in a more solvent-accessible H site. The result is that the H site is less shielded from solvents [35, 36].
Plasmodium vivax and P. falciparum DHFR
Plasmodium vivax is becoming resistant to chloroquine and other antifolates, such as pyrimethamine [37–39]. The target enzyme of pyrimethamine is dihydrofolate reductase (DHFR). It was demonstrated that the resistance to pyrimethamine is caused by point mutation . Interestingly, the crystal structure of DHFR enzyme from P. vivax was published by Kongsaeree et al in 2005 , where they indicated that the principal difference between DHFR wild type and mutant, implicated in the antifolate resistance, is a structural change in the chain of Asn-108, and this steric conflict is not present in P. falciparum.
Antifolates, such as pyrimethamine and cycloguanil, are the most exploited class of anti-malarials. To date, the most widely used antifolate is a combination of pyrimethamine, a dihydrofolate reductase (DHFR) inhibitor, and sulphadoxine, a dihydropteroate synthase (DHPS) inhibitor. DHFR and DHPS are two enzymes that belong to the folate biosynthetic pathway . Although their synergistic action results in enhanced activity, their efficacy is seriously compromised by drug resistance. As a major advance towards the understanding of drug resistance in malaria, it has been demonstrated that drug resistance is due to single and multiple mutations of various amino acids in the DHFR and DHPS active sites in P. vivax as well as P. falciparum [43, 44]. The analysis of the gene encoding P. falciparum DHFR from resistant parasites suggested that antifolate resistance arises from point mutations in the DHFR domain, mainly at positions 16, 51, 59, 108, and 164. It has been demonstrated that parasites with mutations at 16 and 108 have developed resistance to cycloguanil, with a thousand-fold drop in the Ki compared with the wild type, whereas the Ki of pyrimethamine is almost unaffected. On the contrary, there is cross-resistance between the drugs when multiple mutations at position 51, 59, 108 and 164 occur.
Combined homology modelling and molecular dynamics simulation studies proposed how pyrimethamine, cycloguanil and WR99210 (a third-generation antifolate) bind to wild type and resistant mutant P. falciparum and P. vivax DHFRs [45, 46]. Crystal structure determination of the malarial DHFRs in complex with antifolates have confirmed and strengthened the proposed binding modes [46, 47].
Virtual docking procedure
The different steps of the virtual docking procedure will be described in the following section.
The initial coordinates for all the target structures are obtained from Brookhaven protein database. Depending upon the inclusion of the significant residues, active site is defined as 8.0 – 10Ǻ around the co-crystallized ligands.
The X-ray crystal structure of GST utilized is 1Q4J . 1Q4J is a homodimer with two chains A and B. The crystal water molecules are eliminated from the protein. The active site is defined as 8Ǻ around the co-crystallized ligand: GTX, all significant residues are included in the binding site. Re-docking with GTX ligand is performed for further optimization of the target parameters as well as software parameters.
Plasmodium vivax DHFR (PvDHFR) and Plasmodium falciparum DHFR (PfDHFR)
The protein structures used in this investigation are the crystal structures of wild-type P. falciparum DHFR (PDB code 1J3I) and of its N51I+C59R+S108N+I164L highly resistant mutant (PDB code 1J3K), both in complex with NADPH and the potent inhibitor WR99210, and the structures of wild type P. vivax DHFR (PDB code 2BL9) and of its S58R+S117N resistant mutant (PDB code 2BLC) in complex with pyrimethamine and des-chloro pyrimethamine, respectively [41, 46]. The structures were cut at residue Asn231, which corresponds to the DHFR domain of the bifunctional DHFR-TS structure. Of the dimer, unit B was chosen because of its less missing residues. Met 1 was built as in unit A, and the position of missing residues from Asp87 to Asn90 was modelled with Modeller software . At this purpose, the enzyme sequence with the four missing residues was aligned with the complete sequence, and ten models were generated with the Modeller software using 1J3I as template. The best model according to Prosa II was saved, and the coordinates of the four missing residues were inserted back in the original crystal structure. For the quadruple mutant of P. falciparum DHFR, the missing segment from residue 81 to 97 was taken from the wild type structure. P. vivax DHFR was prepared using the same methodology. Residues E24 and K48, which have truncated side chains in the original crystal structures, were assigned based on standard Amber topologies of amino acids. Residues from 84 to 105 missing in the double mutant structure were taken from the wild type structure.
All water molecules in the crystal structure were removed except for two conserved waters embedded into the protein (corresponding to W1249 and W1250 in the original 1J3I crystal structure) and close to the important residue D54. Hydrogens were added to the structures using the internal coordinates of the AMBER all-atom data base. All Lys and Arg residues were positively charged and Glu and Asp residues negatively charged. All calculations were performed with AMBER9 and the ff03 force field . The parameters of the cofactor NADPH were taken from previous simulations [47, 49].
The structures prepared as described above were refined with energy minimization, employing a distance-dependent dielectric constant e = 4r and a cutoff of 12 Å for non-bonded interactions. Firstly, 500 steps of conjugate gradient energy minimization were performed on the hydrogen atoms only, followed by 5,000 steps of minimization on the entire structure. Then, in order to refine the position of the hydrogen atoms added with Amber, 50 ps molecular dynamics at 300°K was performed on the hydrogens by adding strong restraints on the heavy atoms. Finally, 5000 steps of minimization were performed without restraints. All minimizations were performed on the protein structures with the corresponding antifolates bound in the active site (WR99210 or Pyr). For the antifolates, partial atomic charges on atoms were calculated with the AM1-BCC method  implemented in the antechAmber module of Amber9. Atom types and missing force-field parameters of the ligands were assigned based on the General Amber force-field (gaff) .
The compound library used for WISDOM was obtained from the ZINC database [52, 53]. The ZINC database is a collection of 4.3 million chemical compounds from different vendors. ZINC library has been chosen because it is an open source database, and the data are available in different file formats (Sybyl mol2 format, sdf and smiles). So, basically, ZINC provides virtual compounds ready for virtual screening. A total of 4.3 million compounds were downloaded from the ZINC database and screened against targets mentioned in Table 1.
FlexX: Docking software
The docking software used in the current study is FlexX [54, 55]. It is extremely fast, robust and highly configurable computer program for predicting protein-ligand interactions. Standard parameter settings are used except for two cases: "Place particles"  and "Maximum overlap volume". These two parameters were subject to deliberate variation with FlexX. Since every target has a unique response to docking software parameters set, there is no generic solution to the parameter sets. Initial optimization experiments were done to arrive at a parameter set which gave best results in redocking experiment for a particular target.
Setting up the platform before large-scale virtual screening
Re-docking results of different targets in different parameter sets of FlexX
Redocking results against quadrupule mutant DHFR
RMSD for best solution
Rank for Best RMSD solution
Score for best RMSD
Illustrates re-docking results against wild type DHFR
Best Score (kJ/mol)
RMSD for best solution
Rank for Best RMSD solution
Score for best RMSD
Represents top compounds by docking against PfGST_a with interactions to key amino acids
Interaction to Key AA'
Virtual screening on the EGEE grid infrastructure
After setting up the docking platform, virtual screening was performed on 4.3 million compounds against the targets specified in Table 1. Screening 4.3 million compounds on multiple target structures demands huge computation and storage resource power. EGEE and its related grid infrastructures (AuverGrid, EELA, EUChinaGrid and EUMedGrid) provided the resources required for executing the data challenge. Deployment strategies and WISDOM production environment were developed for submission of jobs and retrieval of results on the EGEE grid. More information on deployment and wisdom production environment can be found in Jacq et al . The significant achievement on the grid side is the improved WISDOM production environment, which enabled smooth and successful deployment of docking jobs on the grid. The major difference between our previous deployments (WISDOM-I and the data challenge on avian flu) is the automatic resubmission of the docking jobs on the grid. Besides the enormous gain in the computing resources available, grid infrastructures enable also to store the tera bytes of scientific data and to share this data between the research laboratories located not only in different countries but also on different continents.
Docking scores of the ten best solutions after clustering
Interaction information between protein and ligands of the ten best solutions,
Binding modes of the ten best solutions.
Moreover, the ranking process is the integral part of the docking software. FlexX have a post processing optimization of the docking solution and clustering. Clustering in FlexX is based on RMSD, angle, and distance deviation (default values are used for the clustering; the necessity of clustering docking poses is discussed in ).
Database schema to store the results
During the first deployments (WISDOM-I and data challenges on Avian Flu) the results were stored on the grid storage elements using the grid data management, this format made the analysis of the results particularly difficult, which left some room for improvement.
The real interest of such a solution is that the useful data are immediately available for query and analysis during the process. The usage of relational database along with SQL eases the selection of the best compounds as they can be selected accordingly to any attribute of the database tables. As almost all programming languages offer the ability to access database management systems through APIs, it will also ease the interoperability with web servers, for instance, if one wants to be able to monitor and view the data on a web interface.
Strategies adopted for analysing the results
Result analysis is performed to identify a small number of promising compounds that can be tested further. During WISDOM-I, the compounds with best docking scores were visualized manually and interestingly observed that some of the top scoring compounds were making interactions to the key residues but the binding modes of the compounds were not optimal and not comparable with docking poses of co-crystallized ligands, one of the reason may be due to the rigid nature of the receptor. Consequently, the result analysis took place by first extracting the compounds based on docking scores and then by rescoring the best docked ligands with more sophisticated scoring functions. At this purpose, for this project, an automated refinement and rescoring procedure developed by Rastelli et al , which refines ligand-target complexes with molecular mechanics and molecular dynamics, and then calculates the binding free energies according to MM-PBSA and MM-GBSA methods are utilized. Such procedure, called BEAR (Binding Estimation After Refinement)  significantly improved the overall procedure and resulted in the identification of plasmepsin inhibitors (WISDOM-I). Hence, the same procedure was used to extract the best 5,000 (against GST), 15,000 (against DHFR) compounds based on docking scoring values. MM-PBSA and MM-GBSA (Molecular mechanics-Poisson Boltzmann surface area and Molecular Mechanics-Generalized Born surface area) procedures calculate the absolute free energies for non-covalent interactions of protein and ligand in solution by using force field based molecular mechanics method [59, 60].
Results and discussion
Docking results of PfGST are represented in Table 5. Six amino acids were considered to be responsible for the activity of the target: Tyr9, Gln58, Val59, Ser72, Gln71 and Lys15. Chemical compounds interacting with these amino acids were of significance and hence computed. All ten top scoring compounds displayed in Table 5 made interactions to these key amino acids. A binary scoring mode was adopted for the residue reactions in Table 5, column 3: "0" represents false (no interaction with the specified amino acid) and "1" represents true (either a hydrogen bond or a hydrophobic interaction, was made). From Table 5, it is clear that all the top scoring compounds are making interactions with at least one of the key amino acids. These observations are later compared to the standard protein ligand interaction information obtained from ligand plots displayed in Figure 1. This particular method not only allowed us to select compounds based on scoring but also based on interaction information (hydrophobic and hydrophilic interactions), which is very significant from the structural point of view for the identification of hits.
Diversity analysis of top scoring compounds for PfGST and PfDHFR
Modeling aspects of final hits against PfGST
PfGST interactions against best compounds are displayed
Type of interaction
1. N--O & O---N
1. H-don & H-acc
1: 2.85 & 2.81
2. O---OG & O---N
2. H-acc & H-acc
2: 2.51 & 2.87
1. N---OE & O---NE
1. H-don & H-acc
1: 1.93 & 3.02
1. O---N & O---OG
1. H-acc & H-acc
1: 3.02 & 2.89
1. O---NZ & O---NZ
1. H-acc & H-acc
1. 2.97 & 2.93
3. O---N & O---OG
3. H-acc & H-acc
3: 2.89 & 2.83
1. N--O & O---N
1. H-don & H-acc
1: 2.11 & 3.05
2. O---OG & O---N
2. H-acc & H-acc
2: 3.04 & 2.92
1. ASP105 (B)
1. O---NZ & O---NZ
1. H-acc & H-acc
1: 2.95 & 3.28
3. O---N & O---OG
3. H-acc & H-acc
3: 3.30 & 2.92
2. O---N & O---OG
2. H-acc &. H-acc
2: 2.92 & 2.82
Conclusion and prospective
In this paper, the potential impact of grid infrastructures for in silico drug discovery is demonstrated. The effort described here focussed on two malaria biological targets, DHFR and GST, but at much reduced cost, the same strategy can be applied to produce focused compound libraries for any other malaria targets. Through this article, the intention is to draw the attention of the research communities working on these neglected diseases to the opportunity offered by this grid-enabled virtual screening approach for producing short lists of particularly promising molecules, which can be tested in vitro at a reduced cost. Besides the use of the computational grids for producing large amount of scientific data, grids form a platform for the convenient global exchange of the chemical data produced.
One major bottleneck in large scale screening experiments is the handling of large data output of these experiments. As shown in this paper, this problem is addressed by parsing the results into a MySQL database, storing the docking score as well as atom-to-atom interaction between the protein and ligand. The interaction information plays a vital role in selecting the hits, since it takes the compound counterpart, the protein, into consideration as well.
Diversity analysis (using finger prints, MACCS keys and Tanimoto Coefficient) was performed on the best compounds based on docking results and revealed that the compounds are quite diverse and sensible for further analysis. Future works aims at two things: an extension of the virtual screening pipeline by additional analysis methods and an even tighter integration of in silico prediction of candidate molecules and experimental validation of the compounds.
As an extension of the in silico pipeline for virtual screening, data handling and data analysis methods have to be improved significantly. The storage of docking results in the database was just a first step; in the future it is expected to be able to learn from in silico experiments by analysing entire series of docking experiments. Techniques supporting the judicious selection of chemical compounds from the large scale screening data will need to be improved. New features of drug-like molecules such as their potential toxicity will have to be addressed by an extension of the in silico screening through predictive toxicology systems. On the long run, it is likely to extend the in silico drug discovery workflow by models for predictive ADME. The rather proprietary nature of the drug discovery process in the pharmaceutical industry resulted in limited availability of models in this field, but initiatives such as the European Innovative Medicine Initiative (IMI) might help to foster broader uptake of computational models for predictive ADME (and toxicity) by altruistic research initiatives, such as WISDOM.
The current study may serve as a template for finding hits cost effectively by utilizing the in silico methods against multiple targets at the same time. The WISDOM collaboration is also keen to receive requests for docking other malarial targets according to the procedure described in this paper.
Information on WISDOM collaboration can be found at http://wisdom.healthgrid.org.
The authors acknowledge the contribution of Emmanuel Medernach (AuverGrid), Ignacio Blanquer (EELA), Gabri Aparico (EELA), Enrico Fattibene (EUChinaGrid), Kostas Koumantaros (EUMedGrid) and Domenico Vicinanza (EUMedGrid) who supported the deployment on several grid infrastructures.
The Enabling Grids for E-sciencE (EGEE) project is co-funded by the European Commission under contract INFSO-RI-031688. Auvergrid is a project funded by the Conseil Regional d'Auvergne. The BioinfoGRID project is co-funded by the European Commission under contract INFSO-RI-026808. The EMBRACE project is funded by the European Commission within its FP6 Programme, under the thematic area "Life sciences, genomics and biotechnology for health", contract number LHSG-CT-2004-512092.
We gratefully acknowledge the support of BioSolveIT who provided more than 6,000 free licenses for their commercial docking program FlexX.
- Research and Training in Tropical Diseases. [http://www.who.int/tdr/diseases/malaria/default.htm]
- Drugs for Neglected Diseases Initiative. [http://www.dndi.org/]
- Bleicher KH, Boehm HJ, Mueller K, Alanine AI: Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov. 2003, 2: 369-378.View ArticlePubMedGoogle Scholar
- Boehm HJ, Schneider G: Virtual screening for bioactive molecules. 2000, New York: John Wiley & Sons, IncView ArticleGoogle Scholar
- Spencer RW: High throughput virtual screening of historic collections on the file size, biological targets and file diversity. Biotechnol Bioeng. 1998, 61: 61-67.View ArticlePubMedGoogle Scholar
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The protein data bank. Nucleic Acids Res. 2000, 28: 235-242.PubMed CentralView ArticlePubMedGoogle Scholar
- Hoeltje HD, Sippl W, Rognan D, Folkers G: Molecular Modeling, Basics Principles And Applications. 2003, New York: John Wiley & Sons, IncGoogle Scholar
- Bajorath J: Integration of virtual and high-throughput screening. Nat Rev Drug Discov. 2002, 1: 882-894.View ArticlePubMedGoogle Scholar
- Buyya R, Branson K, Giddy J, Abramson D: The virtual laboratory. A toolset to enable distributed molecular modeling for drug design on the worldwide grid. Concurrency Computat Pract Exper. 2003, 15: 1-25.View ArticleGoogle Scholar
- Jacq N, Salzemann J, Legre' Y, Reichstadt M, Jacq F, Zimmermann M, Maass A, Sridhar M, Kasam V, Schwichtenberg H, Hofmann M, Breton V: Demonstration of in silico docking at a large scale on grid infrastructure. Stud Health Technol Inform. 2006, 120: 155-157.PubMedGoogle Scholar
- Foster I, Kesselman C: Computational Grids. The Grid: Blueprint for a New Computing Infrastructure. 1999, San Fransisco: Morgan Kaufmann PublishersGoogle Scholar
- Enabling Grids for E-Science. [http://www.eu-egee.org]
- Auvergrid. [http://www.auvergrid.fr]
- E-Science grid facility for Europe and Latin America. [http://www.eu-eela.org]
- EUChinagrid. [http://www.euchinagrid.org]
- EUmedgrid. [http://www.eumedgrid.org]
- The Smallpox Research Grid. [http://www.chem.ox.ac.uk/smallpox/news.html]
- The Anthrax Research Project. [http://www.chem.ox.ac.uk/anthrax/]
- United Devices Cancer Research Project. [http://www.computerworld.com/action/article.do?command=viewArticleBasic%26articleId=9045698]
- Richards WG: Virtual screening grid computing: The screensaver project. Nat Rev Drug Discov. 2002, 1: 551-555.View ArticlePubMedGoogle Scholar
- Jacq N, Salzemann J, Legré Y, Reichstadt M, Jacq F, Medernach E, Zimmermann M, Maaß A, Sridhar M, Vinod-Kusam K, Montagnat J, Schwichtenberg H, Hofmann M, Breton V: Grid enabled virtual screening against malaria. J Grid Comput. 2008, 1: 29-43.View ArticleGoogle Scholar
- Kasam V, Zimmermann M, Maaß A, Schwichtenberg H, Wolf A, Jacq N, Breton V, Hofmann M: Design of plasmepsin inhibitors: A virtual high throughput screening approach on the EGEE grid. J Chem Inf Model. 2007, 47: 1818-1828.View ArticlePubMedGoogle Scholar
- Degliesposti G, Kasam V, Da Costa A, Kang HK, Kim DW, Breton V, Doman Kim D, Rastelli G: Design and discovery of novel plasmepsin inhibitors using an automated workflow on large scale grids. Chem Med Chem.Google Scholar
- Kasam V, Salzemann J, Jacq N, Mass A, Breton V: Large scale deployment of molecular docking application on computational grid infrastructures for combating malaria. Proceedings of the Seventh IEEE International Symposium on Cluster Computing and the Grid: May 14–17 2007; Rio de Janeiro. 2007, IEEE Computer Society, 691-700.View ArticleGoogle Scholar
- Spread of malaria by P. Vivax. [http://usachppm.apgea.army.mil/Documents/FACT/18-041-0107_Vivax_Malaria.pdf]
- Muller S: Redox and antioxidant systems of the malaria parasite Plasmodium falciparum. Mol Microbiol. 2004, 53 (5): 1291-1305.View ArticlePubMedGoogle Scholar
- Becker K, Tilley L, Vennerstrom JL, Roberts D: Oxidative stress in malaria parasite-infected erythrocytes, host-parasite interactions. Int J Parasitol. 2004, 34: 163-189.View ArticlePubMedGoogle Scholar
- Cardoso RFM, Daniels DS, Bruns CM, Tainer JA: Characterization of the electrophile binding site and substrate binding mode of 26 kDa glutathione S-transferase form Schistosoma japonicum. Proteins. 2003, 5: 137-146.View ArticleGoogle Scholar
- Sheenan D, Meade G, Foley VM, Dowd CA: Structure function and evolution of glutathione transferases, implication for classification of non-mammalian members of an ancient super family. Biochem J. 2001, 360: 1-16.View ArticleGoogle Scholar
- Srivastva P, Puri SK, Kamboj KK, Pandey VC: Glutathione S-transferase activity in malaria parasites. Trop Med Int Health. 1999, 4: 251-254.View ArticleGoogle Scholar
- Dubois VL, Platel DF, Pauly G, Tribouley-Duret J: Plasmodium berghei, implication of intracellular glutathione and its related enzyme in chloroquine resistance in vivo. Exp Parasitol. 1995, 81 (1): 117-124.View ArticlePubMedGoogle Scholar
- Miller LH, Baruch LD, Marsh K, Doumbo OK: The pathogenic basis of malaria. Nature. 2002, 415: 673-679.View ArticlePubMedGoogle Scholar
- Fritz-Wolf K, Becker A, Rahlfs S, Harwalt P, Schirmer RH, Kansch W, Becker K: X-ray structure of glutathione S-transferase from the malarial parasite Plasmodium falciparum. Proc Natl Acad Sci U S A. 2003, 100: 13821-13826.PubMed CentralView ArticlePubMedGoogle Scholar
- Perbandt M, Burmeister C, Walter RD, Betzel C, Liebau E: Native and inhibited structure of a Mu class related glutathione S- transferase from Plasmodium falciparum. J Biol Chem. 2004, 279 (2): 1336-1342.View ArticlePubMedGoogle Scholar
- Koehler RT, Villar HO, Bauer KE, Higgins DL: Ligand based protein alignment and isozyme specificity of glutathione S-transferase inhibitors. Proteins. 1997, 28: 202-216.View ArticlePubMedGoogle Scholar
- Liebau E, Bergmann B, Campbell AM, Teesdale-Spittle P, Brophy PM, Luersen K, Walter RD: The glutathione S-transferase from Plasmodium falciparum. Mol Biochem Parasitol. 2002, 124: 85-90.View ArticlePubMedGoogle Scholar
- Baird JK: Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother. 2004, 48: 4075-4083.PubMed CentralView ArticlePubMedGoogle Scholar
- Ahlm C, Wistrom J, Carlsson H: Chloroquine-resistant Plasmodium vivax in Borneo. J Travel Med. 1996, 3: 124-View ArticlePubMedGoogle Scholar
- Young MD, Burgess RW: Pyrimethamine resistance in Plasmodium vivax malaria. Bull World Health Organ. 1959, 20 (1): 27-36.PubMed CentralPubMedGoogle Scholar
- Imwong M, Pukrittakayamee S, Looareesuwan S, Pasvol G, Poirreiz J, White NJ, Sno G: Association of genetic mutations in Plasmodium vivax DHFR with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlatos. Antimicrob Agents Chemother. 2001, 45: 3122-3127.PubMed CentralView ArticlePubMedGoogle Scholar
- Kongsaeree P, Khongsuk P, Leartsakulpanich U, Chitnumsub P, Tarnchompoo B, Walkinshaw MD, Yuthavong Y: Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci USA. 2005, 102: 13046-13051.PubMed CentralView ArticlePubMedGoogle Scholar
- White N: Drug resistance in malaria. Br Med Bull. 1998, 54: 703-715.View ArticlePubMedGoogle Scholar
- Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV: Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA. 1997, 94: 1124-1129.PubMed CentralView ArticlePubMedGoogle Scholar
- Yuthavong Y: Basis for antifolate action and resistance in malaria. Microbes Infect. 2002, 4 (2): 175-182.View ArticlePubMedGoogle Scholar
- Rastelli G, Sirawaraporn W, Sompornpisut P, Vilaivan T, Kamchonwongpaisan S, Quarrel R, Lowe G, Thebtaranonth Y, Yuthavong Y: Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with Plasmodium falciparum dihydrofolate reductase: structural basis of antifolate resistance. Bioorg Med Chem. 2000, 8: 1117-1128.View ArticlePubMedGoogle Scholar
- Rastelli G, Pacchioni S, Sirawaraporn W, Sirawaraporn R, Parenti MD, Ferrari AM: Structure of Plasmodium vivax dihydrofolate reductase determined by homology modeling and molecular dynamics refinement. Bioorg Med Chem Lett. 2003, 13: 3257-3260.View ArticlePubMedGoogle Scholar
- Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, Vanichtanankul J, Sirawaraporn W, Taylor P, Walkinshaw MD, Yuthavong Y: Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol. 2003, 10: 357-365.View ArticlePubMedGoogle Scholar
- Modeller. [http://salilab.org/modeller/]
- Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Onufriev A, Simmerling C, Wang B, Woods R: The amber biomolecular simulation programs. J Comput Chem. 2005, 26: 1668-1688.PubMed CentralView ArticlePubMedGoogle Scholar
- Jakalian A, Bush BL, Jack DB, Bayly CI: Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I. Method. J Comput Chem. 2000, 21: 132-146.View ArticleGoogle Scholar
- Wang J, Wolf RM, Caldwell JW, Kollamn PA, Case DA: Development and testing of a general amber force field. J Comput Chem. 2004, 25: 1157-1174.View ArticlePubMedGoogle Scholar
- ZINC: A free database for virtual screening. [http://blaster.docking.org/zinc/]
- Irwin JJ, Shoichet BK: ZINC – A free database of commercially available compounds for virtual screening. J Chem Inf Model. 2005, 45: 177-182.PubMed CentralView ArticlePubMedGoogle Scholar
- Rarey M, Kramer B, Lengauer T, Klebe G: A fast flexible docking method using an incremental construction algorithm. J Mol Biol. 1996, 261: 470-489.View ArticlePubMedGoogle Scholar
- FlexX Version 2.0; BioSolveIT Gmbh. [http://www.biosolveit.de/]
- Rarey M, Kramer B, Lengauer T: The particle concept: placing discrete water molecules during protein-ligand docking predictions. Proteins. 1999, 34 (1): 17-28.View ArticlePubMedGoogle Scholar
- Ferrari AM, Degliesposti G, Sgobba M, Rastelli G: Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors. Bioorg Med Chem. 2007, 15: 7865-7877.View ArticlePubMedGoogle Scholar
- Rastelli G, Degliesposti G, Del Rio A, Sgobba M: Binding estimation after refinement, a new automated procedure for the refinement and rescoring of docked ligands in virtual screening. Chem Biol Drug Des. 2009, 73: 283-286.View ArticlePubMedGoogle Scholar
- Srinivasan J, Thomas E, Cheatham I, Cieplak P, Kollman PA, Case DA: Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices. J Am Chem Soc. 1998, 120: 9401-9409.View ArticleGoogle Scholar
- Kollman PA, Massova , Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE: Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res. 2000, 33: 889-97.View ArticlePubMedGoogle Scholar
- UCSF Chimera. [http://www.cgl.ucsf.edu/chimera/]
- Molecular Operating Environment. [http://www.chemcomp.com/]
- Barnard JM, Downs GM, Willett PJ: Chemical similarity searching. Chem Inf Comput Sci. 1998, 38: 983-996.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.